OncoMed Pharmaceuticals, Inc. To Present Data For Notch1 Program At The 19th European Hematology Association Congress

REDWOOD CITY, Calif., June 4, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, will present new data at the upcoming 19th European Hematology Association (EHA) Congress related to the company’s anti-Notch1 (OMP-52M51) clinical-stage program.

Help employers find you! Check out all the jobs and post your resume.